Tag: Cann Group Limited
Cann Group expects record revenue growth of 111% in FY23
Pharmaceutical company Cann Group Limited announced its FY23 unaudited results, with its operating revenue expected to be approximately $13.5 million, representing growth of 111 per cent or 2.1 times compared to the prior year revenue.
Cann granted GMP manufacturing licence for Mildura facility
The Therapeutic Goods Administration (TGA) has granted Cann Group Limited a GMP licence to manufacture therapeutic goods, which includes GMP testing at its Mildura facility.
Cann...
Cann Group supplies medicinal cannabis for Australian clinical trial for advanced cancer patients
Cann Group Limited is supplying medicinal cannabis for Australian clinical trial assessing quality of life impacts for advanced cancer patients.
The trial, which is being...
Featured Article
Australian manufacturing in 2025: Challenges and pathways to progress
The Australian manufacturing sector, long considered the backbone of the nation’s economy, is standing at a crossroads in 2025.
